Business

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

PLYMOUTH MEETING, Pa., July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to

articleInovio Pharmaceuticals, Inc.July 26, 20235/company/inovio-pharmaceuticals-inc/news/inovio-to-report-second-quarter-2023-financial-results-on-august-9-2023
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

About this update from Inovio Pharmaceuticals, Inc.

[{"type":"text","content":"PLYMOUTH MEETING, Pa., July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.\nA live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.\nAbout INOVIO\nINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.\nContacts\nMedia: Jennie Willson (267) 429-8567 [email protected]: Thomas Hong (267) 440-4298 [email protected]\n \n View original content:https://www.prnewswire.com/news-releases/inovio-to-report-second-quarter-2023-financial-results-on-august-9-2023-301886336.html\nSOURCE INOVIO Pharmaceuticals, Inc.","length":2584,"tagName":"div"}]

More updates from Inovio Pharmaceuticals, Inc.